Big Opportunities For API Inspection Firms

BMI believes there is significant global growth potential for third party active pharmaceutical ingredient (API) inspection firms over the next few years. This is in light of the fact that multinational pharmaceutical companies are increasingly outsourcing production abroad, numbers of counterfeit pharmaceuticals appear to be on the rise, and there are growing concerns over the quality of drugs produced in less developed

To read the full article, please choose one of the following options: